- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04136821
The Long-term Effects of Oceanix™ on Resistance Training Adaptations
The Long-term Effects of Oceanix™ Supplementation on Oxidative Stress, Performance, Body Composition and Safety Metrics
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will examine the effects of Oceanix™, an antioxidant supplement, on muscle performance, immune and endocrine function, recovery and safety in participants undergoing resistance training. Measures of muscle performance will include isometric testing in the bench-press and mid-thigh pull and ground reaction forces in the counter movement- and squat-jump. Markers of immune function will include salivary immunoglobulin A (IgA) as well as serum total antioxidant capacity (TAC) and superoxide dismutase (SOD) while endocrine function will be measured by salivary cortisol and testosterone. Recovery will be measure by plasma creatine kinase (CK) and perceptual measures will be assessed using a validated perceived recovery status (PRS) scale. Safety metrics will be indicated by a comprehensive metabolic panel (CMP), complete blood count (CBC), and urinalysis (UA). Additionally, the modified Borg Rating of Perceived Exertion (RPE) will be administered following each training session to grade physical exertion and monitor progression of the training protocol.
This study will be a double blind parallel, randomized placebo-controlled trial. The investigators will request participation from 25 male and female participants (40-60 % mixture of each) ranging from 18 to 45 years old who are active (i.e. 30 minutes per week of vigorous activity classified as greater than 75 % of their HR max 3 days • week-1). The exclusion criteria will include having a BMI of 30 or more kg/m²; having cardiovascular, metabolic, or endocrine disease; undergone surgery that affects digestion and absorption, smoking, drinking heavily (> 7 and > 14 drinks per week for women and men, respectively), women who are pregnant or planning to be pregnant; taking medication to control blood pressure, lipids, and blood glucose; have taken or currently taking anabolic-androgenic steroids. The investigators will also exclude individuals using antioxidant supplements, NSAIDS, or nutritional supplements known to stimulate recovery or muscle mass gains, heart disease, prescription medications, dietary supplements that enhance body strength, muscle, immune function, muscle recovery, or soreness. Additionally, individuals cannot have allergies for seaweeds or marine sources or any dietary supplements or take any psychiatric supplements or blood thinners.
Participants will be baselined and post-tested at week zero and again after 6 weeks of training, respectively. However, on weeks 2 and 5, participants will experience an overreaching phase to induce stress, and run through specific tests to gauge recovery at the end of those specific weeks. Variables collected at these time points are described below.
Primary variables:
- Muscle, fat mass, and bone density as indicated on DXA
- Upper body strength, velocity, and power on the bench press.
- Lower body strength and power on a dual force plate.
- Vertical jump performance on a dual force plate.
- Movement mechanics and stability using a combination of motion analysis and a dual force plate.
Secondary Variables
- CBC, CMP, Urinalysis
- Vital signs (blood pressure)
- Adverse Events Scale
- PRS and RPE scales
At the end of weeks 2 and 5 participants will be examined for their perceived recovery, soreness, serum markers of muscle damage (creatine kinase), and oxidative stress markers (SOD and Total Antioxidant Status). The rationale for the time points is to introduce extreme stressors in the early and late stages of the training protocol. Variables collected at these time points are described below.
Secondary variables
- Muscle damage (blood creatine kinase), soreness, and recovery.
- Immune function (IGA) , endocrine function (cortisol and testosterone), and oxidative stress (SOD and total antioxidant status).
- PRS scale
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33607
- Applied Science & Performance Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physically active males and females aged 18 to 45 years.
- Volunteers are deemed active if they engage in 30 minutes of vigorous activity, classified as greater than 75 % of their HR max, 3 days • week-1.
Exclusion Criteria:
- > BMI of 30 or more kg/m²
- Cardiovascular, metabolic, or endocrine disease
- Undergone surgery that affects digestion and absorption
- Smoking
- Drinking heavily (> 7 and > 14 drinks per week for women and men, respectively)
- Women who are pregnant or planning to be pregnant
- Taking medication to control blood pressure, lipids, and blood glucose
- Have taken or currently taking anabolic-androgenic steroids
- Individuals using antioxidant supplements, NSAIDS, or nutritional supplements known to stimulate recovery or muscle mass gains, heart disease, prescription medications, dietary supplements that enhance body strength, muscle, immune function, muscle recovery, or soreness
- Allergies for seaweeds or marine sources
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
|
6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
|
|
Experimental: Oceanix™
Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
|
6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in muscle strength
Time Frame: Pre, Week 2, Week 5, Week 6
|
Assessed by isometric mid-thigh pull and isometric bench-press
|
Pre, Week 2, Week 5, Week 6
|
|
Changes in muscle power
Time Frame: Pre, Week 2, Week 5, Week 6
|
Assessed through ground reaction forces during countermovement- and squat-jumps on a force plate.
|
Pre, Week 2, Week 5, Week 6
|
|
Total Antioxidant Capacity (TAC)
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining total antioxidant capacity in fasted whole blood samples.
The TAC measures the overall collective power of the blood to neutralize free radicals.
|
Pre, Week 2, Week 5, Week 6
|
|
Superoxide Dimutase (SOD)
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining superoxide dimutase in fasted whole blood samples.
This is another protective antioxidant enzyme measured from whole blood.
|
Pre, Week 2, Week 5, Week 6
|
|
Creatine Kinase (CK)
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining creatine kinase in fasted whole blood samples.
This is biomarker an indirect measure of muscle damage.
|
Pre, Week 2, Week 5, Week 6
|
|
Body Composition
Time Frame: Pre and Week 6
|
Body Composition will be assessed via dual-energy x-ray absorptiometry (DXA).
Using this method, changes in total-, lean-, and fat-mass will be examined.
|
Pre and Week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rating of Perceived Exertion (RPE)
Time Frame: Following every resistance training session throughout the study.
|
Assessed through a visual analog scale (modified Borg Scale) numbered 0-10 with visual descriptors.
For example, at 0 the descriptor is "rest" and at 10 the descriptor is "maximal exertion".
|
Following every resistance training session throughout the study.
|
|
Perceived Recovery Status (PRS)
Time Frame: Prior to every resistance training session throughout the study.
|
Assessed through a visual analog scale numbered 0-10 with visual descriptors.
For example, at 0 the descriptor is "very poorly recovered/extremely tired" and at 10 the descriptor is "very well recovered/highly energetic".
|
Prior to every resistance training session throughout the study.
|
|
Immunoglobulin A (IgA)
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining the concentration of IgA in fasted saliva samples.
|
Pre, Week 2, Week 5, Week 6
|
|
Cortisol
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining the concentration of Cortisol in fasted saliva samples.
|
Pre, Week 2, Week 5, Week 6
|
|
Testosterone
Time Frame: Pre, Week 2, Week 5, Week 6
|
Experimental outcome examining the concentration of testosterone in fasted saliva samples.
|
Pre, Week 2, Week 5, Week 6
|
|
Complete Blood Count
Time Frame: Pre and Week 6
|
Complete blood count with differential will be assessed via fasted whole blood samples.
|
Pre and Week 6
|
|
Comprehensive Metabolic Panel
Time Frame: Pre and Week 6
|
Comprehensive metabolic panel will be assessed via fasted whole blood samples.
|
Pre and Week 6
|
|
Urinalysis
Time Frame: Pre and Week 6.
|
Urinalysis gross examinations will be conducted prior to and at the completion of the study (Week 6).
|
Pre and Week 6.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resting Systolic Blood Pressure
Time Frame: Pre and Week 6
|
Change in resting systolic blood pressure.
|
Pre and Week 6
|
|
Resting Diastolic Blood Pressure
Time Frame: Pre and Week 6
|
Change in resting diastolic blood pressure.
|
Pre and Week 6
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ASPI0519
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.